| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910822 | Lung Cancer | 2015 | 8 Pages |
Abstract
Low baseline sVEGFR2 and sVEGFR3 were predictive for PFS benefit from cediranib, whereas increases in VEGF-A and decreases in sVEGFR2 or sVEGFR3 levels from baseline to on-treatment were predictive of an OS benefit from cediranib in chemotherapy treated NSCLC patients. Validation of these results is warranted.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christina L. Addison, Keyue Ding, Lesley Seymour, Huijun Zhao, Scott A. Laurie, Frances A. Shepherd, Glenwood D. Goss, Penelope A. Bradbury,